📊 IRIX Key Takeaways
Is IRIX a Good Investment? Thesis Analysis
IRIX is experiencing deteriorating operational performance with negative operating income, negative free cash flow, and declining revenue despite reasonable liquidity. The company is burning cash operationally while maintaining a modest equity base, creating significant downside risk if losses persist.
Why Buy IRIX? Key Strengths
- Adequate gross margin of 36.2% indicates viable underlying product economics
- Strong liquidity position with 1.94x current ratio and $5.6M cash provides runway
- Conservative debt structure with 0.21x debt-to-equity ratio limits financial distress risk
IRIX Investment Risks to Consider
- Negative operating income of -$2.6M and negative net margin of -11.2% show structural unprofitability
- Operating cash flow of -$2.7M indicates the business is not self-sustaining and burning capital
- Revenue declining 6.2% YoY combined with losses suggests loss of market share or demand weakness
- Negative ROE of -90.9% and ROA of -15.0% demonstrate poor capital utilization and value destruction
- Interest coverage of -17.5x reflects inability to service debt from operations
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF
- Revenue stabilization and return to growth
- Operating margin recovery toward breakeven
- Cash burn rate and runway remaining at current burn rate
IRIX Financial Metrics
💡 AI Analyst Insight
IRIDEX CORP presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
IRIX Profitability Ratios
IRIX vs Healthcare Sector
How IRIDEX CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IRIX Overvalued or Undervalued?
Based on fundamental analysis, IRIDEX CORP has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IRIX Balance Sheet & Liquidity
IRIX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: IRIDEX CORP's revenue has grown significantly by 19% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.59 indicates the company is currently unprofitable.
IRIX Growth Metrics (YoY)
IRIX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.6M | -$1.6M | $-0.09 |
| Q2 2025 | $12.6M | -$994.0K | $-0.06 |
| Q1 2025 | $11.8M | -$1.7M | $-0.10 |
| Q3 2024 | $11.6M | -$1.8M | $-0.11 |
| Q2 2024 | $12.6M | -$2.7M | $-0.16 |
| Q1 2024 | $11.8M | -$2.1M | $-0.13 |
| Q3 2023 | $12.9M | -$1.8M | $-0.11 |
| Q2 2023 | $12.9M | -$2.2M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IRIX Capital Allocation
IRIX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for IRIDEX CORP (CIK: 0001006045)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRIX
What is the AI rating for IRIX?
IRIDEX CORP (IRIX) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRIX's key strengths?
Claude: Adequate gross margin of 36.2% indicates viable underlying product economics. Strong liquidity position with 1.94x current ratio and $5.6M cash provides runway.
What are the risks of investing in IRIX?
Claude: Negative operating income of -$2.6M and negative net margin of -11.2% show structural unprofitability. Operating cash flow of -$2.7M indicates the business is not self-sustaining and burning capital.
What is IRIX's revenue and growth?
IRIDEX CORP reported revenue of $38.0M.
Does IRIX pay dividends?
IRIDEX CORP does not currently pay dividends.
Where can I find IRIX SEC filings?
Official SEC filings for IRIDEX CORP (CIK: 0001006045) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRIX's EPS?
IRIDEX CORP has a diluted EPS of $-0.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRIX a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, IRIDEX CORP has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IRIX stock overvalued or undervalued?
Valuation metrics for IRIX: ROE of -90.9% (sector avg: 15%), net margin of -11.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRIX stock in 2026?
Our dual AI analysis gives IRIDEX CORP a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IRIX's free cash flow?
IRIDEX CORP's operating cash flow is $-2.7M, with capital expenditures of $37.0K. FCF margin is -7.2%.
How does IRIX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -11.2% (avg: 12%), ROE -90.9% (avg: 15%), current ratio 1.94 (avg: 2).